Leadership

Dr. Eric Harrison MD

Dr Harrison curates a high resolution three dimensional heart imaging database (coronary computed tomography angiogram or CCTA) of 5,000 cases and created the Sherlock Program for predicting cardiac prognosis based on plaque morphology, composition, and function to predict cardiac events. He started the company PrivaCors to develop this concept nationally with artificial intelligence. PrivaCors was chosen by IBM Watson Healthcare to join their 24 company collaborative to implement AI in medical imaging and EKGs. He co-founded the International Cardio-Oncology Society a 501 (3) (c) and promoted our Global International Meeting in Tampa last year and Brazil this year. He founded Cardio-Orthopaedics, a new subspecialty of cardiology to contain the cardiac risk of orthopaedic Total Joint Arthroplasty (TJA) surgery. This program in collaboration with Florida Orthopaedic Institution has resulted in presentation at the International Society for Technology in Arthroplasty (ISTA) in London last year and in Toronto this year.

Dr. Alexander Lyon MA BM BCh PhD FRCP FHFA

Dr. Alexander Lyon is a Senior Lecturer in Cardiology at Imperial College London and a Consultant Cardiologist at the Royal Brompton Hospital. His clinical interests are in the field of heart failure, cardio-oncology including chemotherapy cardiomyopathy and the cardiovascular complications of modern cancer therapies, Takotsubo syndrome and the effects of major stresses of the heart, and the development of novel therapeutics including gene therapy for chronic heart failure. Alex has published over 180 scientific papers in peer-reviewed journals, several book chapters in cardiology textbooks including the chapter on cardiotoxicity of tyrosine kinase inhibitors in the latest edition of the ESC Textbook of Cardiology. He is a deputy editor of the European Heart Journal, an associate editor of the European Journal of Heart Failure, international advisor to the journal JACC Cardio-Oncology and his H-index is 44.
Alex is the clinical lead for the Cardio-Oncology service at the Royal Brompton Hospital since 2011, specialising in surveillance and cardio protection from modern cancer drugs, risk stratification and treatment of all cardiac complications of cancer treatment.
Alex is the current president of the British Cardio-Oncology Society, recently appointed a board member of International Cardio-Oncology Society (ICOS – 2021), chair-elect European Society of Cardiology (ESC) Council of Cardio-Oncology (2020-2022) and he is the cardiology advisor to the charity Macmillan Cancer. Alex is a co-investigator of the first Leducq Cardio-Oncology Transatlantic Research Network funded from 2020-2025 ($6M).
Alex is a co-chair of the first ESC Cardio-Oncology Guideline which will be published in 2022.
Alex completed a full 4 year term on the board of the Heart Failure Association of the ESC (2016-2020), and he initiated and was the chair of the Heart Failure Association Cardio-Oncology Study Group. He is a co-author of the ESC Position Statement on Cardio-Oncology, the ESC Cardio-Oncology Council article on the setting up and delivery of Cardio-Oncology services and the 2020 ESMO guidelines on the management of cardiac diseases in cancer patients. He is a member of the International Cardio-Oncology Society and Alex was co-chair of the 2017 Global Cardio-Oncology Summit which hosted 325 specialists from 33 countries at the Royal College of Physicians in London in September 2017.

Dr. Daniel Lenihan, MD

Dr Lenihan has been active in cardio-oncology and heart failure for over 20 years. The main focus of these efforts have included hemodynamic assessments, angiogenic growth factor response, novel cardiac biomarkers as well as optimal methods to prevent or detect heart failure at the earliest stage possible in patients undergoing treatment for cancer. His current research projects include early phase clinical trials in cardio-oncology, heart failure and amyloidosis. He is the Principal Investigator of the PROTECT study looking at cardiac safety in patients undergoing proteasome inhibitor treatment for relapsed multiple myeloma and the recently completed PREDICT study, a large multicenter prospective study examining the role of cardiac biomarkers for the detection of cardiotoxicity during anthracycline based therapy. In addition, He is intimately involved in the latest treatment trials for cardiac amyloidosis. He recently moved to Washington University in St. Louis to enhance and expand the Cardio-Oncology Center of Excellence. He is at the forefront of concerted efforts to develop a viable Cardio-Oncology fellowship training program and continue to foster collaboration among a host of colleagues both regionally, nationally, and throughout the world. He is the current president of the International Cardio-Oncology Society (ICOS), a professional association whose primary goal is to eliminate cardiac disease as a barrier to effective cancer therapy and is a Deputy Editor for the Journal of the American College of Cardiology: Cardio-Oncology a newly created JACC family of journals. His current research projects include early phase clinical trials in cardio-oncology, heart failure and amyloidosis. He is the Principal Investigator of the PROTECT study looking at cardiac safety in patients undergoing proteasome inhibitor treatment for relapsed multiple myeloma and the recently completed PREDICT study, a large multicenter prospective study examining the role of cardiac biomarkers for the detection of cardiotoxicity during anthracycline based therapy. In addition, He is intimately involved in the latest treatment trials for cardiac amyloidosis. He recently moved to Washington University in St. Louis to enhance and expand the Cardio-Oncology Center of Excellence. He is at the forefront of concerted efforts to develop a viable Cardio-Oncology fellowship training program and continue to foster collaboration among a host of colleagues both regionally, nationally, and throughout the world. He is the current president of the International Cardio-Oncology Society (ICOS), a professional association whose primary goal is to eliminate cardiac disease as a barrier to effective cancer therapy and is a Deputy Editor for the Journal of the American College of Cardiology: Cardio-Oncology a newly created JACC family of journals. Contact at cardio-oncologydoc@protonmail.com.

Steve Casselli

Steve’s background is in nonprofit leadership. He served as the Director of Admissions for a small graduate school in Philadelphia and then as the Senior Minister of a local church for twenty years in Tampa, Florida. There he met the Chairman of the ICOS Board, Dr. Eric Harrison who introduced him to the work. He has been married for over thirty years to his wife Missy, and has three grown children, two of whom are also married.

He grew up in Columbus, Ohio, so remains a die-hard Buckeye fan. Having played college lacrosse and coached for ten years he has been an advocate for the growth of the sport in Tampa. Steve’s academic background is in Theological Studies. He has published in both academic and popular journals, while his dissertation was published as a book-length monograph. The history and theology of the Protestant Reformation is an ongoing area of interest.

Joseph R. Carver, MD

Joseph R. Carver, MD, FACC is a Board Certified cardiologist. He is the Founding Editor of the American Journal of Managed Care and was a Senior Corporate Medical Director at Aetna U.S. Healthcare from 1992-2001 where he was responsible for new program development and directed the National Medical Excellence Program.From 1999-2001, he was Co-chairperson of the New Jersey and Michigan Working Groups that established voluntary agreements among the insurers in those states to cover the routine costs of clinical trial participation for cancer patients. He is one of the Founding Editors of Cardio-oncology Journal. He currently is the Bernard Fishman Clinical Professor of Medicine at the Abramson Cancer Center of the University of Pennsylvania, the Chief Operating Officer of the Abramson Family Cancer Research Institute of the Abramson Cancer Center of the University of Pennsylvania and the Chief of Staff of the Abramson Cancer Center. He is the clinical director of the Penn Cardio-oncology Center of Excellence and his clinical practice is in the subspecialty of Cardio-oncology. He was the recipient of the IS Ravdin Master Clinician Award at Penn in 2012 and is one of the founding members of Penn Medicine’s Academy of Master Clinicians. He is one of the Founding Editors of Cardio-oncology Journal. He currently is the Bernard Fishman Clinical Professor of Medicine at the Abramson Cancer Center of the University of Pennsylvania, the Chief Operating Officer of the Abramson Family Cancer Research Institute of the Abramson Cancer Center of the University of Pennsylvania and the Chief of Staff of the Abramson Cancer Center. He is the clinical director of the Penn Cardio-oncology Center of Excellence and his clinical practice is in the subspecialty of Cardio-oncology. He was the recipient of the IS Ravdin Master Clinician Award at Penn in 2012 and is one of the founding members of Penn Medicine’s Academy of Master Clinicians.

Dr. Susan Dent

Dr. Dent attended McMaster University Medical School in Hamilton, Ontario, Canada and completed her residency training in Internal Medicine and Medical Oncology at the Ottawa Hospital, University of Ottawa, Ontario, Canada. She subsequently completed a post graduate research fellowship year in clinical trials at the Canadian Cancer Trials Group (CCTG) in Kingston, Ontario, and was subsequently appointed as a staff medical oncologist at the Northwestern Ontario Cancer Center in Thunder Bay, Ontario.

In 2001, Dr. Dent returned to Ottawa, where she specialized in the treatment of breast cancer. In 2008, Dr. Dent, working with her cardiology colleagues, established a multidisciplinary cardio-oncology clinic in Ottawa; the first of its kind in Canada. In 2011, she founded the Canadian Cardiac Oncology Network (CCON), a not-for-profit organization devoted to optimization of cancer care for patients without compromising cardiovascular health. (www.cardiaconcology.ca).

Anita Arnold, MD, MBA

Dr. Arnold graduated from the New York College of Osteopathic Medicine in 1984. She also completed her MBA at George Washington University in 2012. Anita is currently serving as Assistant Professor of Medicine, Florida State University and the Director of Cardio-Oncology at Lee Heath in Fort Meyers, the largest healthcare system in Southwest Florida with over 100 locations offering medical services.

She has a passion for women’s health, healthcare reform with fairness for patients and providers, local healthcare cardiovascular initiatives and the field of cardio-oncology. Her career has focused mostly on intervention but for the past six years Anita has been deeply involved in cardio-oncology, having started the program at Lee Heath and serving as the Director of Cardio-Oncology.She has a passion for women’s health, healthcare reform with fairness for patients and providers, local healthcare cardiovascular initiatives and the field of cardio-oncology. Her career has focused mostly on intervention but for the past six years Anita has been deeply involved in cardio-oncology, having started the program at Lee Heath and serving as the Director of Cardio-Oncology.In addition, Anita has been active in promoting cardio-oncology through her advocacy work at the State and Federal levels, and in her service with the ACC. She has been involved with the ACC Cardio-Oncology Council and has served as the Chair of the Advocacy Working Group since its inception.

Michael Fradley, MD

Dr. Fradley is an attending cardiologist/electrophysiologist and Medical Director, Penn Cardio-Oncology Program and Associate Professor of Clinical Medicine at the University of Pennsylvania. He is board certified in Cardiovascular Disease as well as Internal Medicine.

He then went on to complete fellowships in both Cardiology and Clinical Cardiac Electrophysiology at Massachusetts General Hospital. Dr. Fradley’s current research interests involve the treatment and prevention of cardiovascular disease in cancer patients and survivors. He has published multiple articles and also served on many committees including the Massachusetts Medical Society Committee on Medical Education and the University of South Florida LCME Faculty Affairs committee. He is also heavily involved in medical education, teaching cardiovascular pathophysiology to second year medical students, and serving as the medical director for the Harvey Simulation course.

He completed his undergraduate training, with a major in Molecular Biophysics and Biochemistry, at Yale University, where he graduated cum laude with distinction in major. He received his MD degree at the Johns Hopkins School of Medicine, and then remained at Johns Hopkins, completing his residency in Internal Medicine through the Osler Medical Residency Program.Dr. Fradley is an attending cardiologist/electrophysiologist and an Assistant Professor of Medicine at the University of South Florida, Morsani College of Medicine.  He serves as the director of the joint USF-Moffitt Cancer Center Cardio-Oncology Program. He is board certified in Cardiovascular Disease, clinical cardiac electrophysiology, as well as Internal Medicine.He completed his undergraduate training, with a major in Molecular Biophysics and Biochemistry, at Yale University, where he graduated cum laude with distinction in major. He received his MD degree at the Johns Hopkins School of Medicine, and then remained at Johns Hopkins, completing his residency in Internal Medicine through the Osler Medical Residency Program.He then went on to complete fellowships in both Cardiology and Clinical Cardiac Electrophysiology at Massachusetts General Hospital. Dr. Fradley’s current research interests involve the treatment and prevention of cardiovascular disease in cancer patients and survivors. He has published multiple articles and also served on many committees including the Massachusetts Medical Society Committee on Medical Education and the University of South Florida LCME Faculty Affairs committee. He is also heavily involved in medical education, teaching cardiovascular pathophysiology to second year medical students, and serving as the medical director for the Harvey Simulation course.

Teresa López-Fernández, MD

She is certified in cardio-oncology
(ICOS) and Advanced Cardiac Imaging (ESC). Dr. López Fernández is the current president of the Imaging Association of the Spanish Society of Cardiology. She is the founder and chair of the Spanish Cardio-Oncology Working Group at the Spanish Society of Cardiology (SEC). She is a board member of the European Society of Cardiology (ESC) Council of Cardio-Oncology. Dr. López-Fernández has published multiple articles and book chapters and also served as a speaker on many national and
international conferences.

Joseph R. Carver, MD, FACC

Joseph R. Carver, MD, FACC is a Board Certified cardiologist. He is the Founding Editor of the American Journal of Managed Care and was a Senior Corporate Medical Director at Aetna U.S. Healthcare from 1992-2001 where he was responsible for new program development and directed the National Medical Excellence Program.

From 1999-2001, he was Co-chairperson of the New Jersey and Michigan Working Groups that established voluntary agreements among the insurers in those states to cover the routine costs of clinical trial participation for cancer patients. He is one of the Founding Editors of Cardio-oncology Journal.

He currently is the Bernard Fishman Clinical Professor of Medicine at the Abramson Cancer Center of the University of Pennsylvania, the Chief Operating Officer of the Abramson Family Cancer Research Institute of the Abramson Cancer Center of the University of Pennsylvania and the Chief of Staff of the Abramson Cancer Center. He is the Director of the Thalheimer Cardio-oncology Center at the Abramson Cancer Center and his clinical practice is in the subspecialty of Cardio-oncology. He was the recipient of the IS Ravdin Master Clinician Award at Penn in 2012 and is one of the founding members of Penn Medicine’s Academy of Master Clinicians. He received the ICOS Thomas Force Award in 2019.